A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumorsToshio Shimizu, Kazuhiko Nakagawa, Joanna Horobin et al.|Cancer Chemotherapy and Pharmacology|2016Cited by 109
Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid TumorsMasayuki Takeda, Kazuto Nishio, Takayuki Takahama et al.|The Oncologist|2020Cited by 95